2023
Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis
Chow R, Yin L, Baqri W, Huang R, Boldt G, Younus J, Lock M, Prsic E, Zimmermann C, Herrstedt J. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis. Supportive Care In Cancer 2023, 31: 505. PMID: 37535218, DOI: 10.1007/s00520-023-07978-y.Peer-Reviewed Original ResearchConceptsChemotherapy-induced nauseaIndividual patient dataDay 4Individual patient-level dataPatient dataPatient-level dataStepwise logistic regressionEmetogenic chemotherapyChemotherapy regimenChemotherapy regimensPatient demographicsCochrane CENTRALResultsA totalOverall prevalenceCINVNauseaVomitingPatientsEligible articlesSystematic reviewAntineoplastic agentsStudy authorsLogistic regressionMethodsThis reviewSignificant risk
2020
The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
Presley C, Shahzad H, Canavan M, Prsic E, Saphire M, Wang S, Davidoff A. The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC). Journal Of Clinical Oncology 2020, 38: e24009-e24009. DOI: 10.1200/jco.2020.38.15_suppl.e24009.Peer-Reviewed Original ResearchAdvanced-stage lung cancerDoublet chemotherapyEOL groupOlder adultsIntensity groupInitial chemotherapy regimenInitial chemotherapy treatmentPlatinum-based doubletsPlatinum-doublet chemotherapyFirst-line therapyUse of chemotherapyMajority of patientsEOL care preferencesStage lung cancerMain outcome measuresNon-Hispanic whitesMedicare registryChemotherapy regimenLine therapyCisplatin chemotherapyLung cancerChemotherapy treatmentAge 66Outcome measuresCare trajectories